Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β.
dc.contributor.author | Mullen, Lisa | |
dc.contributor.author | Rigby, Anne | |
dc.contributor.author | Sclanders, Michelle | |
dc.contributor.author | Adams, Gill | |
dc.contributor.author | Mittal, Gayatri | |
dc.contributor.author | Colston, Julia | |
dc.contributor.author | Fatah, Rewas | |
dc.contributor.author | Subang, Cristina | |
dc.contributor.author | Foster, Julie | |
dc.contributor.author | Francis-West, Philippa | |
dc.contributor.author | Köster, Mario | |
dc.contributor.author | Hauser, Hansjörg | |
dc.contributor.author | Layward, Lorna | |
dc.contributor.author | Vessillier, Sandrine | |
dc.contributor.author | Annenkov, Alex | |
dc.contributor.author | Al-Izki, Sarah | |
dc.contributor.author | Pryce, Gareth | |
dc.contributor.author | Bolton, Chris | |
dc.contributor.author | Baker, David | |
dc.contributor.author | Gould, David J | |
dc.contributor.author | Chernajovsky, Yuti | |
dc.date.accessioned | 2014-05-13T08:18:00Z | |
dc.date.available | 2014-05-13T08:18:00Z | |
dc.date.issued | 2014-01 | |
dc.identifier.citation | Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. 2014, 11 (1):5-16 Expert Opin Drug Deliv | en |
dc.identifier.issn | 1744-7593 | |
dc.identifier.pmid | 24073618 | |
dc.identifier.doi | 10.1517/17425247.2013.839655 | |
dc.identifier.uri | http://hdl.handle.net/10033/316733 | |
dc.description.abstract | Targeting cytokines to sites of disease has clear advantages because it increases their therapeutic index. We designed fusion proteins of the latent-associated peptide (LAP) derived from TGF-β with various cytokines via a matrix metalloproteinase (MMP) cleavage site. This design confers latency, increased half-life and targeting to sites of inflammation. The aim of this study is to determine whether this approach can be applied to cytokines of different molecular structures and sizes. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Expert opinion on drug delivery | en |
dc.title | Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. | en |
dc.type | Article | en |
dc.contributor.department | Experimental Rheumatology, Charité University Medicine, Berlin, Germany | en |
dc.identifier.journal | Expert opinion on drug delivery | en |
refterms.dateFOA | 2015-01-15T00:00:00Z | |
html.description.abstract | Targeting cytokines to sites of disease has clear advantages because it increases their therapeutic index. We designed fusion proteins of the latent-associated peptide (LAP) derived from TGF-β with various cytokines via a matrix metalloproteinase (MMP) cleavage site. This design confers latency, increased half-life and targeting to sites of inflammation. The aim of this study is to determine whether this approach can be applied to cytokines of different molecular structures and sizes. |